ACE Inhibitors in Congestive Heart Failure

Introduction to ACE Inhibitors

The American College of Cardiology recommends ACE inhibitors as first-line therapy for all patients with heart failure with reduced ejection fraction (HFrEF) in conjunction with beta-blockers and aldosterone antagonists in selected patients, due to their ability to reduce both mortality and morbidity by blocking the renin-angiotensin-aldosterone system 1, 2, 5

ACE inhibitors work by blocking the conversion of angiotensin I to angiotensin II, resulting in increased bradykinin levels, which contributes to beneficial vasodilation 1, 2
Randomized controlled trials have demonstrated that ACE inhibitors provide significant reduction in all-cause mortality across all severity levels of heart failure 1, 2
ACE inhibitors reduce hospitalizations for heart failure by preventing disease progression 1, 3
The American Heart Association notes that ACE inhibitors improve exercise capacity and reduce dyspnea and fatigue in patients with HFrEF, as evidenced by improved NYHA functional class 3 and enhanced overall sense of well-being 4

The European Society of Cardiology recommends that all patients with symptomatic HFrEF (NYHA class I-IV) should receive ACE inhibitors 1, 3
Patients with asymptomatic left ventricular systolic dysfunction should receive ACE inhibitors to prevent progression to symptomatic heart failure 4
Post-myocardial infarction patients with reduced ejection fraction should receive ACE inhibitors to prevent heart failure development 6
The dosing strategy for ACE inhibitors involves starting with a low dose and titrating to target doses used in clinical trials, such as captopril (6.25 mg three times daily, target 50-100 mg three times daily) and enalapril (2.5 mg twice daily, target 10-20 mg twice daily) 1, 3

The American College of Cardiology advises that ACE inhibitors are contraindicated in patients with life-threatening angioedema or anuric renal failure during previous ACE inhibitor exposure, pregnancy or planning pregnancy, and bilateral renal artery stenosis 2, 4
Patients with systolic blood pressure <90-100 mmHg, serum creatinine >2.5 mg/dL, or serum potassium >5.0-5.5 mEq/L should be monitored closely for potential adverse effects 1, 2, 3
Monitoring requirements include checking blood pressure, renal function, and serum potassium at baseline, after dose increases, and periodically during maintenance 3

For patients who cannot tolerate ACE inhibitors due to cough or angioedema, angiotensin receptor blockers (ARBs) are recommended as an alternative (Class I, Level of Evidence A) 1, 2
Angiotensin receptor-neprilysin inhibitors (ARNI) such as sacubitril/valsartan have shown superior outcomes in patients who tolerate ACE inhibitors, with a 20% reduction in cardiovascular death or heart failure hospitalization compared to enalapril (Class I, Level of Evidence B-R) 5, 7